Table 2.

ACR response rates at week 12

	Placebo (n = 33)	ASP5094 (n = 32)
ACR50 responders, n (%)a	6 (18.2)	2 (6.3)
Difference (90% CI)	−11.9 (−25.0, 1.2)
P valueb	0.258
ACR20 responders, n (%)c	16 (48.5)	12 (37.5)
Difference (90% CI)	−11.0 (− 31.1, 9.1)
P valueb	0.455
ACR70 responders, n (%)c	2 (6.1)	1 (3.1)
Difference (90% CI)	−2.9 (−11.4, 5.6)
P valueb	1.000

^aPrimary efficacy endpoint, assessed via nonresponder imputation

^bP values based on Fisher’s exact test

^cSecondary efficacy endpoint, assessed via last observation carried forward technique

ACR American College of Rheumatology, CI confidence interval